2018
DOI: 10.1002/cncr.31354
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Patients with Ph-neg ALL treated with allo-PBSCT benefit from the use of ATG in terms of improved GRFS. Its use may, therefore, be considered in this setting. Cancer 2018;124:2523-33. © 2018 American Cancer Society.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
8

Relationship

3
5

Authors

Journals

citations
Cited by 18 publications
(10 citation statements)
references
References 36 publications
0
10
0
Order By: Relevance
“…Once again, prospective, randomized studies addressing this issue were not specifically focused on adults with ALL. More recently, a retrospective analysis has been performed on behalf of the EBMT, including patients with Ph-negative ALL treated with either MSD-HSCT or URD-HSCT in CR1 [57]. The use of ATG was associated with reduced incidence of chronic GVHD without significant impact on LFS or OS.…”
Section: Source Of Stem Cellsmentioning
confidence: 99%
“…Once again, prospective, randomized studies addressing this issue were not specifically focused on adults with ALL. More recently, a retrospective analysis has been performed on behalf of the EBMT, including patients with Ph-negative ALL treated with either MSD-HSCT or URD-HSCT in CR1 [57]. The use of ATG was associated with reduced incidence of chronic GVHD without significant impact on LFS or OS.…”
Section: Source Of Stem Cellsmentioning
confidence: 99%
“…The beneficial effect on GVHD was also partially counterbalanced by increased risk of relapse associated with the use of ATG. Although such effect was observed in only one of the randomised trials, increased risk of relapse has recently been reported by Czerw et al [26] in a large retrospective study including patients with Phnegative ALL. Therefore, it may be speculated that consequences of the use of ATG differ according to the diagnoses, and patients with ALL, irrespective of the status of Philadelphia chromosome, are particularly susceptible to its effects.…”
Section: Discussionmentioning
confidence: 87%
“…cGVHD requiring any IST has been incorporated into composite endpoints, in recognition of the risk of morbidity and mortality following HCT [6,9,10,12,13,15,16,[22][23][24][25][26][27]. In our cohort, we identified cGVHD requiring IST as an independent risk factor for death (HR, 1.69; 95% CI, 1.16 to 2.46) ( Table 3).…”
Section: Assessing Impact Of Individual Grfs Components On Osmentioning
confidence: 89%
“…Since the initial report by Holtan et al [6], more data are emerging from retrospective single-and multi-center studies [6,9,10,12,13,15,16,[22][23][24][25][26][27] investigating the impact of GRFS on the relative success or failure after allogeneic HCT [5]. The findings raise important questions regarding the use of GRFS in clinical trials given how various definitions and historical (or published) incidences of events in the population affect the findings.…”
Section: Discussionmentioning
confidence: 99%